AR090885A1 - Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple - Google Patents
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multipleInfo
- Publication number
- AR090885A1 AR090885A1 ARP130101459A ARP130101459A AR090885A1 AR 090885 A1 AR090885 A1 AR 090885A1 AR P130101459 A ARP130101459 A AR P130101459A AR P130101459 A ARP130101459 A AR P130101459A AR 090885 A1 AR090885 A1 AR 090885A1
- Authority
- AR
- Argentina
- Prior art keywords
- human patient
- multiple sclerosis
- treatment
- presenting
- human
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 5
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004577 laquinimod Drugs 0.000 title abstract 3
- 206010071068 Clinically isolated syndrome Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 206010008096 Cerebral atrophy Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004112 neuroprotection Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090885A1 true AR090885A1 (es) | 2014-12-10 |
Family
ID=49514859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101459A AR090885A1 (es) | 2012-05-02 | 2013-04-29 | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
Country Status (21)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| TW201345527A (zh) | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途 |
| AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| AU2013329348A1 (en) * | 2012-10-12 | 2015-05-28 | Teva Pharmaceutical Industries Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| HK1215210A1 (zh) | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| HK1218251A1 (zh) * | 2013-02-15 | 2017-02-10 | Teva Pharmaceutical Industries Ltd. | 用拉喹莫德治疗多发性硬化症 |
| EA201591699A1 (ru) | 2013-03-14 | 2016-02-29 | Тева Фармасьютикал Индастриз Лтд. | Кристаллы лаквинимода натрия и улучшенный способ их производства |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| US20150306088A1 (en) * | 2014-04-29 | 2015-10-29 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| WO2020016850A1 (en) * | 2018-07-20 | 2020-01-23 | Merck Patent Gmbh | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US20080118553A1 (en) * | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| US20100322900A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| CN106344576A (zh) * | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| HK1218251A1 (zh) * | 2013-02-15 | 2017-02-10 | Teva Pharmaceutical Industries Ltd. | 用拉喹莫德治疗多发性硬化症 |
-
2013
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en not_active Ceased
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Withdrawn
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20160000775A1 (en) | 2016-01-07 |
| PH12014502447A1 (en) | 2015-01-12 |
| PE20150161A1 (es) | 2015-02-22 |
| UY34775A (es) | 2013-11-29 |
| CN104284663A (zh) | 2015-01-14 |
| CN105832733A (zh) | 2016-08-10 |
| US20130303569A1 (en) | 2013-11-14 |
| WO2013166166A1 (en) | 2013-11-07 |
| TW201804997A (zh) | 2018-02-16 |
| CL2014002935A1 (es) | 2015-03-06 |
| US20150265592A1 (en) | 2015-09-24 |
| IL235337A0 (en) | 2014-12-31 |
| TW201347762A (zh) | 2013-12-01 |
| MX2014013039A (es) | 2015-02-04 |
| KR20150013658A (ko) | 2015-02-05 |
| JP2015515985A (ja) | 2015-06-04 |
| CA2870684A1 (en) | 2013-11-07 |
| JP2017222691A (ja) | 2017-12-21 |
| EA201492010A1 (ru) | 2015-06-30 |
| EP2844255A4 (en) | 2015-10-14 |
| BR112014027010A2 (pt) | 2017-06-27 |
| SG11201406594UA (en) | 2014-11-27 |
| EP2844255A1 (en) | 2015-03-11 |
| ZA201408820B (en) | 2016-06-29 |
| HK1206246A1 (en) | 2016-01-08 |
| AU2013256352A1 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| JP2013155188A5 (cg-RX-API-DMAC7.html) | ||
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| BR112014004339A2 (pt) | suspensão oral | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente | |
| EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой | |
| AR082645A1 (es) | Composiciones y metodos para tratar sindrome mielodisplasico | |
| AR082647A1 (es) | Composiciones y metodos para tratar sindrome mielodisplasico | |
| AR059219A1 (es) | Uso de la suramina para la preparacion de un medicamento para inhibir la neovascularizacion retinal y corneal | |
| AR085988A1 (es) | Tratamientos de la infeccion del virus de la hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |